Singapore-based and Australia-listed Asian Centre for Liver Diseases & Transplantation ("ACLDT") and UPMC, a US$9 billion world-renowned healthcare enterprise based in Pittsburgh, USA, announced that they will collaborate to establish a Comprehensive Transplant Centre (CTC), to be owned and operated by ACLDT, to serve Asia and the Middle East.

The proposed CTC will offer transplantation capabilities in liver, kidney, stem cell and bone marrow. This partnership will improve and enhance the existing capabilities of ACLDT in liver diseases and further offer kidney, stem cell and bone marrow transplant programmes with the technological expertise of UPMC. Being the first of its kind, the establishment of a Singapore-based CTC will advance and transform the way healthcare is provided in Asia.

ACLDT is one of Asia‟s foremost Liver Centres with out-patient facilities and a dedicated in-patient Liver Ward and Intensive Care Unit to complement its successful Living Donor Liver Transplantation Programme thus providing seamless care for patients with liver diseases. Based in Gleneagles Hospital, it is the first private medical centre in South-east Asia to have performed close to 190 living donor liver transplants.

UPMC aims to share its expertise in delivering world-class healthcare, advanced technologies, including telemedicine and electronic medical records, and management skills with ACLDT. Amongst a number of public and private medical companies in Singapore, this collaboration is recognition of ACLDT‟s work and reputation in Asia in delivering high quality and standard of service to patients with liver and gastro diseases.

It is expected the collaboration will help increase ACLDT‟s ability to handle more patients from the region, including the Middle East, widen its scope of transplant activities, raise the quality of clinical outcomes and improve operational efficiencies.

The Asian Centre for Liver Diseases & Transplantation ("ACLDT") was established in 1994 in Singapore. Today, it is one of Asia‟s foremost Liver Centres with out-patient facilities as well as a dedicated in-patient Liver Ward and Intensive Care Unit to complement its highly successful Living Donor Liver Transplantation (LDLT) Programme.

ACLDT is led by renowned hepatobiliary expert and liver transplant surgeon, Dr Tan Kai Chah (Dr K C Tan), who started the Liver Transplant Programme at the King's College Hospital London, the UK. Together with a multi-disciplinary team of experienced specialist physicians and surgeons, Dr Tan developed it into one of the largest in Europe and performed many pioneering operations including the first „split-liver‟ transplant from a single donor to two recipients.

ACLDT is the first private medical centre in South-east Asia to have performed close to 190 living donor liver transplants as at 30 Nov 2011. Dr K C Tan has personally performed more than 600 liver transplants. On average, ACLDT treats 8,000 patients a year, of which over 90% are international patients from South-east Asia, South Asia, Indochina, the Middle East and Russia.

With a team of highly-trained specialists, state-of-the-art facilities and equipment, ACLDT is a one-stop specialist medical hub that provides seamless and comprehensive treatment for adults and children with liver and gastro diseases. Given the vast experience of ACLDT and its highly successful LDLT Programme, it has also become an important referral centre for treatment of acute liver failure and liver transplants.

Gleneagles,6A Napier Road, Gleneagles Hospital Annexe Block #02-37

Tel: +65 64762088 or email: [email protected]